Attached files

file filename
EX-99.1 - EX-99.1 - Bioverativ Inc.ex-99d1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 2, 2017

 

Bioverativ Inc.

 

(Exact name of registrant
as specified in its charter)

 

 

 

 

Delaware

 

 

(State or other jurisdiction of incorporation)

 

001-37859

 

81-3461310

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

 

225 Second Avenue, Waltham, Massachusetts 02451

 

Not Applicable

(Address of principal executive offices; Zip Code)

 

(Former name or former address, if changed since
last report.)

 

 

 

Registrant’s telephone number, including area code: (781) 663-4400

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).    Emerging growth company   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   

 

 


 

Item 2.02    Results of Operations and Financial Condition.

On August 2, 2017, Bioverativ Inc. issued a press release announcing its results of operations and financial condition for the second quarter ended June 30, 2017. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

 

The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

 

Item 9.01    Financial Statements and Exhibits.

 

The exhibit listed on the Exhibit Index immediately preceding such exhibit is furnished as part of this Current Report on Form 8-K.


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

BIOVERATIV INC.

 

 

 

 

 

 

 

By:

/s/ Andrea DiFabio

 

 

Andrea DiFabio

 

 

Executive Vice President,
Chief Legal Officer and Secretary

 

 

 

Date: August 2, 2017

 

 


 

 

EXHIBIT INDEX

 

Exhibit Number

Description

99.1

Bioverativ's press release dated August 2, 2017.